Drug Trial Radar · NCT06659445
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
324
Planned (sponsor's estimate)
Start
Oct 28, 2025
Primary completion
Nov 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- ONL TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of ONL1204 and 2 treatment frequencies in patients with GA associated with AMD. GA associated with AMD is one of the world's leading causes of visual disability and legal blindness globally. Associated with aging, cigarette smoking, obesity, diets low in certain nutrients, a lifestyle related to cardiac risk, and a growing list of genetic factors, AMD is becoming an increasingly prevalent public health concern, especially as the global population ages. ONL1204 is a first-in-class inhibitor of fragment apoptosis stimulator receptor-mediated cell death that has demonstrated protection of multiple retinal cell types in numerous preclinical models of retinal disease, including models of dry AMD.
Conditions
- Geographic Atrophy (GA)
- Age - Related Macular Degeneration (AMD)
Interventions
ONL1204 Opthalmic solutionDrug
Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
Avacincaptad Pegol intravitreal solutionDrug
Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection
ShamOther
Sham injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary EndpointTime frame: From enrollment to the end of treatment at 48 weeks.
Locations
120 sites in 12 countries. Site status is shown where the registry gives one.
Associated Retina Consultants
Gilbert, Arizona · Recruiting
Associated Retina Consultants
Phoenix, Arizona · Recruiting
California Retina Consultants
Bakersfield, California · Recruiting
Retina-Vitreous Associates Medical Group
Beverly Hills, California · Recruiting
Macula and Retina Institute
Glendale, California · Recruiting
Salehi Retina Institute, dba Retina Associates of Southern California
Huntington Beach, California · Recruiting
Desert Retina Consultants
Palm Desert, California · Recruiting
Retinal Consultants Medical Group
Sacramento, California · Recruiting
Bay Area Retina Associates
Walnut Creek, California · Recruiting
Retina Consultants of Southern Colorado
Colorado Springs, Colorado · Recruiting
Retina Group of New England
Waterford, Connecticut · Recruiting
Florida Retina Institute
Orlando, Florida · Recruiting
Retina Specialty Institute
Pensacola, Florida · Recruiting
Retina Group of Florida
Sarasota, Florida · Recruiting
Retina Associates of Florida, LLC
Tampa, Florida · Recruiting
Northwestern Medical Group
Chicago, Illinois · Recruiting
The University of Chicago Medicine Duchossois Center for Advanced Medicine
Chicago, Illinois · Recruiting
Retina Associates, Ltd.
Elmhurst, Illinois · Recruiting
Illinois Retina Associates, S.C.
Oak Park, Illinois · Recruiting
Retina Partners Midwest, P.C.
Carmel, Indiana · Recruiting
The Retina Group of Washington
Chevy Chase, Maryland · Recruiting
Cumberland Valley Retina Consultants
Hagerstown, Maryland · Recruiting
Retina Specialists
Towson, Maryland · Recruiting
Retina Research Institute at New England Retina Consultants
Springfield, Massachusetts · Recruiting
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan · Recruiting
Associated Retinal Consultants, P.C.
Royal Oak, Michigan · Recruiting
Associated Retinal Consultants, P.C.
Traverse City, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
The Retina Institute
St Louis, Missouri · Recruiting
Sierra Eye Associates
Reno, Nevada · Recruiting
Retina Vitreous Surgeons of CNY, PC
Liverpool, New York · Recruiting
Ophthalmic Consultants of Long Island
Oceanside, New York · Recruiting
Retina Associates of Western NY
Rochester, New York · Recruiting
Long Island Vitreoretinal Consultants
Westbury, New York · Recruiting
North Carolina Retina Associates
Cary, North Carolina · Recruiting
Duke Eye Center
Durham, North Carolina · Recruiting
North Carolina Retina Associates
Greenville, North Carolina · Recruiting
North Carolina Retina Associates, S.C.
Wake Forest, North Carolina · Recruiting
Cleveland Clinic Foundation-Cole Eye Institute
Cleveland, Ohio · Recruiting
Erie Retina Research, LLC (Clinic)
Erie, Pennsylvania · Recruiting
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.